Browsing by Author Cloherty, G

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中
Showing results 3 to 12 of 12 < previous 
TitleAuthor(s)Issue Date
 
Dose response with the RNA interference (RNAi) therapy JNJ-3989 combined with nucleos(t)ide analogue (NA) treatment in expanded cohorts of patients (pts) with chronic hepatitis B (CHB)
Proceeding/Conference:Hepatology
Gane, EJLocarnini, SLim, THStrasser, SISievert, WCheng, WThompson, AGiven, BDSchluep, THamilton, JBiermer, MKalmeijer, RBeumont-Mauviel, MLenz, OCloherty, GWong, DKHSchwabe, CJackson, KFerrari, CLai, CLGish, RGYuen, RMF
2019
 
First clinical experience with RNA interference [RNAI]-based triple combination therapy in chronic hepatitis B (CHB): JNJ-73763989 (JNJ-3989), JNJ-56136379 (JNJ-6379) and a nucleos(t)ide analogue (NA)
Proceeding/Conference:Hepatology
Yuen, RMFLocarnini, SGiven, BSchluep, THamilton, JBiermer, MKalmeijer, RBeumont-Mauviel, MLenz, OCloherty, GJackson, KFerrari, CLai, CLLiu, SHKMak, LYWong, DKHTo, WPKo, KLGish, RG
2019
 
First results with RNA interference (RNAi) in chronic hepatitis b (CHB) using ARO-HBV
Proceeding/Conference:Hepatology
Gane, EJLocarnini, SLim, THStrasser, SSievert, WCheng, WThompson, AGiven, BSchluep, THamilton, JLi, ZCloherty, GWong, DKHSchwabe, CJackson, KFerrari, CLai, CLGish, RGYuen, RMF
2018
 
HBV RNA profiles in chronic hepatitis B patients under different disease phases and anti-viral therapy
Journal:Hepatology
Mak, LYCloherty, GWong, DKHGersch, JSeto, WKFung, JYuen, MF
2020
 
Inhibition of hepatitis B surface antigen by RNA interference therapeutic AB-729 in chronic hepatitis B patients correlates with suppression of all HBsAg isoforms and HBV RNA
Proceeding/Conference:Journal of Hepatology
Thi, EPYuen, RMFGane, ESevinsky, HSims, KAnderson, MLam, AMSofia, MJCloherty, GPicchio, G
2021
 
Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation
Journal:Gut
Seto, WKLiu, KSHMak, LYCloherty, GWong, DKHGersch, JLam, YFCheung, KSChow, NKo, KLTo, WPFung, JYuen, MF
2020
 
Short interfering RNA JNJ-3989 combination therapy in chronic hepatitis B shows potent reduction of all viral markers but no correlate was identified for HBsAg reduction and baseline factors
Proceeding/Conference:Journal of Hepatology
Gane, ELocarnini, SLim, THStrasser, SSievert, WCheng, WThompson, AGiven, BSchluep, THamilton, JBiermer, MKalmeijer, RBeumont-Mauviel, MLenz, ODe Ridder, FCloherty, GWong, DKHSchwabe, CJackson, KFerrari, CLai, CLGish, RGYuen, RMF
2021
 
Short interfering RNA JNJ-3989 combination therapy in chronic hepatitis B (CHB) shows potent reduction of all viral markers but no correlate was identified for HBsAg reduction and baseline factors
Proceeding/Conference:APASL 2022, Seoul, Korea, 30 Mar - 3 Apr 2022. Hepatology International
Gane, ELocarnini, SLim, THStrasser, SISievert, WCheng, WThompson, AJGiven, BDSchluep, THamilton, JBiermer, MKalmeijer, RBeumont, MLenz, ORidder, FDCloherty, GWong, DKHSchwabe, CJackson, KFerrari, CLai, CLGish, RYuen, RMF
2022
 
Short term RNA interference therapy in chronic hepatitis B using JNJ-3989 brings majority of patients to HBsAg < 100 IU/ml threshold
Proceeding/Conference:Journal of Hepatology
Yuen, RMFLocarnini, SLim, THStrasser, SSievert, WCheng, WThompson, AGiven, BSchluep, THamilton, JCloherty, GWong, DKHSchwabe, CJackson, KFerrari, CLai, CLGish, RGGane, E
2019
 
Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen suppression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment
Proceeding/Conference:Journal of Hepatology
Gane, ELocarnini, SLim, THStrasser, SSievert, WCheng, WThompson, AGiven, BSchluep, THamilton, JBiermer, MKalmeijer, RBeumont-Mauviel, MLenz, OCloherty, GWong, DKHSchwabe, CJackson, KFerrari, CLai, CLGish, RGYuen, RMF
2020
Showing results 3 to 12 of 12 < previous